GLP-1 'maintenance phase' claims: what the data actually shows

What's this video probably claiming?

Based on the caption and hashtags, @micahandmicha appears to be documenting a personal GLP-1 journey, likely covering the emotional weight of the decision to start, the side effects experienced along the way, and something about a "maintenance" phase, which is the period after reaching a target weight when patients attempt to hold their results on a lower or stable dose. Videos like this almost always include some version of: "it's hard but worth it," a rundown of nausea or GI issues as a rite of passage, and an implicit claim that the drug works as a long-term weight management tool. The #glp1maintenance tag specifically suggests the creator is framing dose reduction or stabilization as a sustainable endpoint. That framing deserves scrutiny, because the clinical data on what happens during and after that phase is a lot less tidy than TikTok makes it look.

What does the science actually show?

GLP-1 receptor agonists do produce meaningful weight loss. In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide 2.4mg weekly produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. Tirzepatide did even better in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), hitting up to 22.5% average weight loss at the highest dose. Those are real, clinically significant numbers. But the maintenance story is where things get complicated. The STEP 4 trial showed that participants who discontinued semaglutide after 20 weeks regained about two-thirds of their lost weight within a year. That's not a side effect, that's the pharmacology. The drug suppresses appetite through GLP-1 receptor activity; stop the drug, the suppression stops. "Maintenance" in this context usually means staying on the medication indefinitely, not transitioning off it, which is a very different thing than what most social media framing implies.

Where does the social media noise diverge from clinical reality?

The gap between TikTok GLP-1 content and clinical reality is significant in a few specific ways. First, the side effect conversation online tends to flatten into a shared-suffering badge of honor, nausea, fatigue, "Ozempic face," when the actual adverse event profile includes more serious signals worth knowing. The SURMOUNT-1 trial reported that 6.2% of tirzepatide participants discontinued due to adverse GI events. Pancreatitis, while rare, has been flagged in post-marketing surveillance. Second, the word "maintenance" gets used loosely. Clinically, dose maintenance usually means staying on a therapeutic dose, not a reduced one that somehow preserves all the benefits. Third, the emotional framing of "it's worth it" is not inherently wrong, but it elides the reality that access, cost, and long-term safety data beyond two to three years remain genuinely open questions. This is still a relatively young drug class for obesity indications, and the five-year and ten-year data simply doesn't exist yet.

What should you actually know?

If you're considering or currently on a GLP-1 for weight management, here's what the literature actually supports. These drugs work while you take them, consistently and in a dose-dependent way. They are not a temporary intervention with a clean exit ramp for most people. The SELECT trial (Lincoff et al., 2023, NEJM) added an important cardiovascular benefit signal for semaglutide in people with established cardiovascular disease and overweight or obesity, a 20% reduction in major adverse cardiac events, which meaningfully expands the clinical rationale beyond weight alone. But long-term safety, particularly thyroid C-cell effects flagged in rodent studies (though not confirmed in human trials so far), muscle mass loss during rapid weight reduction, and the psychological dimensions of appetite suppression all warrant ongoing monitoring. Any "maintenance" plan should be built with a prescribing clinician who is looking at the full picture, not just the number on a scale.